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BACKGROUND: Recently, microRNAs in cancer development have attracted much attention, but their roles in tumorigenesis are still
largely unknown. In this study, a functional role of miR-22 in hepatocellular carcinoma (HCC) development has been identified.
METHODS: Quantitative real-time PCR was used to determine the level of miR-22 transcript in HCC clinical samples, and its correlation
with disease-free survival was determined using Kaplan–Meier method. Restoration of miR-22 expression was carried out in HCC
cell lines to assess its influence on HCC cell proliferation and tumourigenicity.
RESULTS: In the 160 paired HCC tissue samples, miR-22 expression was downregulated in HCC, and low miR-22 expression in
HCC was predictive of poor survival in HCC patients. Functional studies indicated that ectopic expression of miR-22 significantly
inhibits HCC cell proliferation and tumourigenicity. Furthermore, histone deacetylase 4 (HDAC4), known to have critical roles in
cancer development, was proved to be directly targeted and regulated by miR-22. Furthermore, HDAC4 was upregulated in miR-22-
downregulated HCC tissues, suggesting that downregulation of miR-22 might participate in HCC carcinogenesis and progression
through potentiation of HDAC4 expression. In addition, cell proliferation was also suppressed by knockdown of HDAC4
or treatment with HDAC inhibitor trichostatin A in HCC cell lines.
CONCLUSION: miR-22, downregulated in HCC, has an anti-proliferative effect on HCC cells both in vitro and in vivo. Furthermore,
miR-22 may have considerable potential in identification of the prognosis and application of cancer therapy for HCC patients.
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MicroRNAs (miRNAs) are an abundant class of 17–25 nucleotides
small noncoding RNAs. They regulate protein-coding genes
expression at the post-transcriptional level through binding to
the 30 untranslational region (30 UTR) of target mRNAs. Since the
initial observation, B1000 miRNA sequences have been identified
in mammals, but the biological functions of a large part remain
illusive. Growing evidence have suggested that miRNAs have
important roles in the regulation of diverse biological processes
(Bushati and Cohen, 2007), and their deregulation or dysfunction
participates in cancer development and clinical outcomes of cancer
patients (Garzon et al, 2009). However, deregulated miRNAs and
their roles in tumorigenesis are still largely unknown.
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and among the leading causes of cancer-related
deaths (Lai and Lau, 2005). To date, miRNAs have been suggested
to have important roles in HCC development (Gramantieri et al,
2008), and some of them have been identified to correlate with
prognosis or accepted to be potential therapeutic targets (Li et al,
2008; Ji et al, 2009; Xiong et al, 2009). However, elucidating miRNA
deregulation or dysfunction in HCC development is still
an ongoing process. Recently, miR-22 has been shown to be
deregulated in some other types of cancers, such as overexpression
in prostate cancer and downregulation in breast cancer, cholan-
giocarcinoma, and multiple myeloma (Kawahigashi et al, 2009;
Lionetti et al, 2009; Poliseno et al, 2010; Xiong et al, 2010).
However, the roles of miR-22 deregulation in carcinogenesis and
progression remain largely elusive. Hence, in this study, we focus
on the expression and function of miR-22 in HCC development.
In this study, in the 160 HCC and matched non-neoplastic
tissues, we found that miR-22 expression was downregulated, and
its downregulation correlated with decreased disease-free survival
of HCC patients. In HCC cell lines, we further investigated the roles
of miR-22 in cell proliferation both in vitro and in vivo, and found
that miR-22 may function as a tumour suppressor. In addition,
histone deacetylase 4 (HDAC4), known to have critical roles in
cancer development, is proved to be targeted and regulated
by miR-22, indicating that downregulation of miR-22 may involve
in HCC carcinogenesis and progression through potentiation of
HDAC4 expression. Thus, we elucidated the roles of miR-22
downregulation in HCC development and suggested a potential
target in identification of the prognosis and application of cancer
therapy for HCC patients.
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Patients and tissue samples
Surgically resected paired HCC and adjacent non-neoplastic
tissues were collected from 160 primary HCC patients during
operation in 2006 at the Eastern Hepatobiliary Surgery Hospital,
and the details are shown in (Supplementary Table 1). Human
normal liver tissue samples were obtained during operation from
10 normal liver tissue of liver hemangioma patients without
hepatitis virus infection. Surgically removed tissues were quickly
frozen in liquid nitrogen until analysis. All samples were collected
with the informed consent of the patients and the experiments
were approved by the ethics committee of Second Military Medical
University, Shanghai, China. The investigations were conducted
according to the Declaration of Helsinki Principles.
RNA extraction and quantitative RT-PCR
Total RNA, including miRNA, was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. miRNA detection was performed using TaqMan
miRNA assay system (Applied Biosystems, Foster City, CA, USA)
as described by us previously (Chen et al, 2009). The expression of
miR-22 was normalised to that of internal control 18S rRNA by
using 2
 DDCt (cycle threshold) method (Hou et al, 2009; Livak
and Schmittgen, 2001). For miR-22 copy number estimation, we
followed previously reported protocols of detecting miRNA copy
numbers (Chang et al, 2004; Sarasin-Filipowicz et al, 2009).
In brief, we generated standard curves using HPLC- and PAGE-
purified oligoribonucleotides (GenePharma, Shanghai, China)
corresponding to miR-22. The cycle threshold values obtained
from real-time quantitative PCR reactions were converted to
absolute copy number of miR-22 per 20pg of total RNA from liver
tissue, using miR-22 standardisation curves.
Cell culture and transfection
Human HCC cell lines Hep3B and SMMC7721 were obtained
from American Type Culture Collection (Manassas, VA, USA) and
cultured in DMEM (Invitrogen) supplemented with heat-inacti-
vated 10% fetal bovine serum (Invitrogen) at 371C in a humidified
incubator containing 5% CO2. For RNA transfection, 5 10
3
Hep3B or SMMC7721 cells were seeded into each well of 96-well
plate and incubated overnight, then transfected with RNAs
using INTERFERin transfection reagent (Polyplus transfection,
Illkirch, France) at a final concentration of 50nM according to the
manufacturer’s instructions.
miRNA and siRNA
For the gain-of-function study, miR-22 mimics (double-stranded
RNA oligonucleotides) and scrambled control RNA were synthe-
sised by GenePharma. The scrambled control RNA sequences were
50-UUCUCCGAACGUGUCACGUTT-30 (sense) and 50-ACGUGACA
CGUUCGGAGAATT-30 (anti-sense). For human HDAC4 knock-
down, specific small-interfering RNA (siRNA) and scrambled
control RNA were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
Analysis of cell proliferation in vitro
The in vitro cell proliferation of HCC cell lines was measured using
the MTT method (Alley et al, 1988). In brief, cells were seeded into
96-well plates and transfected. In the indicated time periods, 0.1ml
of spent medium was replaced with an equal volume of fresh
medium containing MTT 0.5mgml
 1. Plates were incubated at
371C for 4h, and then the medium was replaced by 0.1ml of DMSO
(Sigma, St Louis, MO, USA) and plates were shaken at room
temperature for 10min. The absorbance was measured at 570nm.
Tumourigenicity assay in nude mice
All experiments involving animals were undertaken in accordance
with the National Institute of Health Guide for the Care and Use of
Laboratory Animals, with the approval of the Scientific Investiga-
tion Board of Second Military Medical University, Shanghai. The
tumourigenicity assay was performed as reported (Su et al, 2009;
Xiong et al, 2009). In detail, 5 10
6 control RNA or miR-22 mimics
transfected HCC Hep3B or SMMC7721 cells were suspended in
0.1ml PBS and then injected subcutaneously into either side of
the posterior flank of the same male BALB/c athymic nude mice
at 4 weeks of age. Tumour growth was measured using caliper
daily, and tumour volume was calculated according to the formula:
volume¼length width
2 0.5.
30 UTR luciferase reporter assay
The human HDAC4 30 UTR luciferase reporter construct was
generated by cloning HDAC4 mRNA 30 UTR sequence into the 30
UTR region of pMIR-Report construct (Ambion, Foster City, CA,
USA). The miR-22 target site-deleted HDAC4 30 UTR luciferase
reporter construct was generated by PCR fragments of HDAC4 30
UTR luciferase reporter construct lacking the target site and
ligated. Hep3B cells were transfected and luciferase activities
were measured as described by us previously (Chen et al, 2009).
Data were normalised by dividing Firefly luciferase activity with
that of Renilla luciferase.
Western blot
Cells and ground tissues were lysed, equalised, loaded, and blotted
as we described previously (Chen et al, 2009). Antibodies specific
to HDAC4, b-actin, and horseradish-peroxidase-coupled second-
ary antibodies were purchased from Santa Cruz Biotechnology.
Densitometric analysis was carried out with Labworks Image
Acquisition and Analysis software (UVP, Upland, CA, USA). The
background was subtracted, and the signals of the detected bands
were normalised to the amount of loading control b-actin band.
The relative value was presented as fold increase over control
sample as indicated.
Statistical analysis
Data are presented as mean±s.d. Statistical comparisons between
experimental groups were analysed by Student’s t-test and a
two-tailed Po0.05 was taken to indicate statistical significance.
For analysing survival of HCC patients, log-rank test in SPSS 17.0
(Chicago, IL, USA) was used with the P-value indicated.
RESULTS
miR-22 is downregulated in HCC
To investigate the roles of miR-22 in HCC development, we
determined the expression level of miR-22 in human normal liver,
as it was reported that a minimum threshold amounts must be
reached for miRNAs to repress their target mRNAs (Brown et al,
2007; Sarasin-Filipowicz et al, 2009). In human distal normal liver
tissue of liver hemangioma obtained from 10 patients during
operation, we found that miR-22 was expressed at about 2 10
3
copies per 20pg total RNA (Figure 1), equivalent of approximately
one cell. Thus, the expression of miR-22 in human normal liver is
much higher than the required amount of miRNA for targets
repression, which is B100 copies per cell (Brown et al, 2007;
Sarasin-Filipowicz et al, 2009).
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and matched adjacent non-neoplastic tissue samples. As shown in
Figure 2, miR-22 expression is significantly decreased in at
least 69% (111 of 160) HCC samples compared with their
matched controls. Hence, we for the first time show that miR-22
is downregulated in HCC, which may contribute to HCC
pathogenesis.
Downregulation of miR-22 correlates with worse prognosis
of HCC patients
Whether miR-22 downregulation correlates with prognosis of HCC
patients was investigated further. As shown in Figure 3, the
Kaplan–Meier method reveals that lower miR-22 expression level
correlates with significantly reduced disease-free survival of the
160 HCC patients. This result further indicates the importance of
miR-22 downregulation in HCC development.
miR-22 suppresses cell proliferation and tumourigenicity
of HCC cell lines
The downregulated miR-22 in HCC prompted us to investigate
whether miR-22 functions as a tumour suppressor. In HCC cell
lines Hep3B and SMMC7721, we found that miR-22 expression was
also markedly decreased (Figure 4A), and restoration of miR-22
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Figure 2 miR-22 expression is downregulated in HCC. Data are shown
as miR-22 expression in 10 human normal liver samples, and 160 paired
HCC and adjacent non-neoplastic tissue samples, with the black line
showing the medium value. **Po0.01.
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Figure 1 Endogenous miR-22 expression level in human normal liver.
Data are shown as miRNA copies per 20pg total RNA (equivalent of
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lines (Figure 4A and B). Furthermore, miR-22-transfected HCC
Hep3B and SMMC7721 cells revealed a delayed tumour formation
and a significant reduction in tumour size compared with that of
control transfectants (Figure 4C). These results show that miR-22
restoration suppresses HCC growth both in vitro and in vivo.
miR-22 targets HDAC4
Next, we sought to investigate the molecular mechanism
responsible for the anti-tumour effect of miR-22 on HCC observed
above. As miRNAs function mainly through inhibiting their target
mRNAs by binding to the 30 UTR, we searched the putative target
genes of miR-22 in TargetScan (http://www.targetscan.org/). In the
330 predicted conserved targets, we found that human HDAC4,
known to have critical roles in cancer development by repressing
differentiation-promoting genes (Wade, 2001), contained putative
conserved miR-22 target site (Figure 5A). To verify whether
HDAC4 is a direct target of miR-22, a dual-luciferase reporter
system was used by co-transfection of miR-22 and a luciferase
reporter plasmid containing the 30 UTR of human HDAC4. As
shown in Figure 5B, the luciferase activity was significantly
inhibited by miR-22 co-transfection, and further miR-22 failed
to inhibit the expression of luciferase construct on target site
deletion, suggesting that miR-22 can directly target the 30 UTR
of HDAC4. Moreover, in HCC Hep3B and SMMC7721 cells,
endogenous expression of HDAC4 protein was suppressed by miR-
22 transfection (Figure 5C), further proving that HDAC4 is directly
targeted and regulated by miR-22 expression.
HDAC4 is upregulated in miR-22-downregulated HCC
tissues
We further compared HDAC4 protein expression between primary
HCC and matched non-neoplastic liver tissue samples, as miR-22
was observed to be downregulated in a large part of HCC tissues
above. In available protein samples of paired HCC tissues, we
found that HDAC4 expression was upregulated in miR-22-down-
regulated HCC tissues (Figure 6). This result further confirms that
endogenous HDAC4 is regulated by miR-22 and miR-22 down-
regulation may participate in HCC carcinogenesis and progression
through potentiation of HDAC4 expression.
Inhibition of HDAC4 suppresses cell proliferation
of HCC cell lines
Next, we evaluated whether HCC cell growth is regulated by
HDAC4 expression, which is targeted by miR-22. As shown in
Figure 7, knockdown of HDAC4 or treatment with HDAC inhibitor
trichostatin A (TSA) suppressed cell proliferation in HCC Hep3B
and SMMC7721 cells. This result further suggests that miR-22 may
suppress HCC cell proliferation at least partially through targeting
HDAC4 expression.
DISCUSSION
In this study, we presented the downregulation of miR-22 in
HCC and suggested the anti-tumour effect of miR-22 in HCC
pathogenesis. Previous reports suggested that miR-22 is also
downregulated in breast cancer, and it suppresses breast cancer
development through directly targeting oestrogen receptor a (ERa)
and downstream signalling (Pandey and Picard, 2009; Xiong et al,
2010). However, miR-22 expression is suggested to be upregulated
in prostate cancer, and its upregulation potentiates phosphatidyl-
inositol 3-kinase-Akt pathway activation (Poliseno et al, 2010).
These controversial results of miR-22 in cancer development may
reflect the diverse roles of miR-22 in different types of cancer.
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of HCC tissues. However, underlying mechanisms that mediate the
downregulation of miR-22 in HCC are still elusive. Epigenetic
alterations, such as DNA methylation or histone modification, in
cancer often mediate the deregulation of tumour suppressors or
oncogenes (Esteller, 2008), and HDAC4 expression potentiated by
miR-22 downregulation may further aggravate the epigenetic
changes in HCC. We will next focus on the mechanisms that
mediate miR-22 downregulation and miR-22-downregulation-
induced epigenetic alterations in HCC pathogenesis.
Downregulation of miR-22 is further suggested to correlate
with reduced disease-free survival of HCC patients. Hence, as HCC
patients with normal miR-22 expression in tumour tissue are
shown to have a better prognosis, determination of miR-22
expression level in HCC tissues may be a novel approach to predict
and identify the prognosis of HCC patients.
The anti-tumour effect of miR-22 in HCC is validated both
in vitro and in vivo, which is that restoration of miR-22 expression
significantly suppresses cell proliferation and tumourigenicity.
Recently, reexpression of miRNAs is believed to hold substantial
clinical potential in cancer therapy (Mishra and Merlino, 2009). As
systemic chemotherapy for HCC has been quite ineffective (Liu
et al, 2006), it is obviously suggested that re-expression of miR-22
may have considerable potential for clinical treatment of HCC
patients, especially for those with poor miR-22 expression in
tumour tissue.
Human HDAC4, an important epigenetic modifier, is further
identified to be a direct target of miR-22 in HCC. A current report
also revealed that miR-22 can repress Max expression and cell-
cycle progression regulated by Myc–Max complex (Ting et al,
2010). These results, together with ERa above, are consistent with
current opinions that a single miRNA can target multiple mRNAs,
named ‘targetome’, to post-transcriptionally regulate gene expres-
sion (Selbach et al, 2008). Hence, it is probable that we are still far
from unveiling the last target of miR-22, and perhaps the
accumulation of all these targets, including Max and HDAC4,
constitutes the phenotype of miR-22 restoration in HCC cells.
According to this presumption, interesting future work may
be carried out to identify the ‘targetome’ and the entire roles of
miR-22 in cancer development.
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